333 related articles for article (PubMed ID: 37459069)
1. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors among patients with heart failure with preserved ejection fraction.
Riaz M; Smith SM; Dietrich EA; Winchester DE; Guo J; Park H
Pharmacotherapy; 2023 Oct; 43(10):1024-1031. PubMed ID: 37459069
[TBL] [Abstract][Full Text] [Related]
2. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
[TBL] [Abstract][Full Text] [Related]
3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
Rao S
Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.
Fu EL; Patorno E; Everett BM; Vaduganathan M; Solomon SD; Levin R; Schneeweiss S; Desai RJ
Eur Heart J; 2023 Jun; 44(24):2216-2230. PubMed ID: 37259575
[TBL] [Abstract][Full Text] [Related]
5. Effects of different sodium-glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a network meta-analysis.
Lan X; Zhu H; Cao Y; Hu Y; Fan X; Zhang K; Wu M
Front Cardiovasc Med; 2024; 11():1379765. PubMed ID: 38845687
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.
Täger T; Atar D; Agewall S; Katus HA; Grundtvig M; Cleland JGF; Clark AL; Fröhlich H; Frankenstein L
Heart Fail Rev; 2021 Nov; 26(6):1421-1435. PubMed ID: 32314085
[TBL] [Abstract][Full Text] [Related]
7. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
[TBL] [Abstract][Full Text] [Related]
8. The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction.
Starr JA; Pinner NA
Ann Pharmacother; 2024 May; 58(5):506-513. PubMed ID: 37542422
[TBL] [Abstract][Full Text] [Related]
9. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
10. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
Arbel R; Aboalhasan E; Hammerman A; Azuri J
Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).
Ryan PB; Buse JB; Schuemie MJ; DeFalco F; Yuan Z; Stang PE; Berlin JA; Rosenthal N
Diabetes Obes Metab; 2018 Nov; 20(11):2585-2597. PubMed ID: 29938883
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction.
Gonzalez J; Bates BA; Setoguchi S; Gerhard T; Dave CV
Cardiovasc Diabetol; 2023 Mar; 22(1):54. PubMed ID: 36899387
[TBL] [Abstract][Full Text] [Related]
14. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
15. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
16. Sodium-Glucose Cotransporter 2 Inhibitors, All-Cause Mortality, and Cardiovascular Outcomes in Adults with Type 2 Diabetes: A Bayesian Meta-Analysis and Meta-Regression.
Odutayo A; da Costa BR; Pereira TV; Garg V; Iskander S; Roble F; Lalji R; Hincapié CA; Akingbade A; Rodrigues M; Agarwal A; Lawendy B; Saadat P; Udell JA; Cosentino F; Grant PJ; Verma S; Jüni P
J Am Heart Assoc; 2021 Sep; 10(18):e019918. PubMed ID: 34514812
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
Nakagawa Y; Kuwahara K
J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
Nam K; Cho DS; Kim H; Kwon B; Yoon Y; Park C; Kim ES; Youn JC; Park SK
Clin Drug Investig; 2023 Jul; 43(7):463-474. PubMed ID: 37365452
[TBL] [Abstract][Full Text] [Related]
19. Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population.
Thorvaldsen T; Ferrannini G; Mellbin L; Benson L; Cosentino F; McMurray JJV; Dahlström U; Lund LH; Savarese G
J Card Fail; 2022 Jul; 28(7):1050-1062. PubMed ID: 35550428
[TBL] [Abstract][Full Text] [Related]
20. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
